Menu
Menu
389574-19-0
Blood Related
C20H21ClFNO3S
409.9 g/mol
Amorphous
Commercial
Ready
Ready
Prasugrel HCl belongs to a group of medicines called antiplatelets or blood thinners. It helps prevent the formation of harmful blood clots and keeps the blood flowing smoothly through your body. Prasugrel HCl also lowers the chances of another heart attack or stroke in people with heart disease, who under angioplasty. It is used to treat people with a recent heart attack or severe heart-related chest pain, who have undergone stenting of the heart. Prasugrel HCl helps to prevent serious heart-related problems like having another heart attack, stroke, or formation of blood clots in stents. This drug can be used as monotherapy or in combination with other medicines. Prasugrel HCl is administered through oral route by way of film-coated tablets.
Prasugrel HCl is a thienopyridine and a prodrug which inhibits ADP receptors by irreversibly acting on the P2Y12 receptor on platelets. The active metabolite of Prasugrel HCl prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. The antiplatelet effect of Prasugrel HCl lasts for the lifespan of platelets.
Ornet Pharmaceuticals, based out of Gujarat, India, is a leading manufacturer and global supplier of Prasugrel HCl API. Driven by technically sound, research-oriented leaders, each with over 2 decades of hands-on experience, Ornet develops and manufactures a wide array of complex APIs catering to multiple categories in its product portfolio, such as anti-diabetics, blood related, hormones, etc. Ornet’s Prasugrel HCl API is the result of the “Quality over Quantity” approach taken by the organization for all R&D and manufacturing practices. This approach, along with the strategically located manufacturing facility in Gujarat, allows for Ornet to be a primary source, both domestically and globally, for all API needs.
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).
